chronic kidney disease
Conditions
Interventions
Regional Citrate Anticoagulation Therapy Group:Sodium Citrate Solution for Anticoagulation, 200ml: 8g per bag
Low Molecular Weight Heparin Anticoagulation Control Group:Low Molecular Weight Heparin Sodium Injection, 0.6ml: 6000 IU
Sponsors
The Seventh Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged between 18 to 75 years old, with no restrictions on gender or ethnicity; 2) Diagnosed with chronic kidney disease stage 5, undergoing regular hemodialysis, 2-3 times per week, for more than 3 months; 3) Concomitant use of anticoagulants (warfarin, NOACs) and/or antiplatelet drugs (aspirin, glycoprotein IIb/IIIa inhibitors, etc.); 4) Signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Individuals allergic to anticoagulant drugs such as citric acid or heparin and its analogs; 2) Contraindications to anticoagulant drugs, such as coagulation disorders, active bleeding, heparin-induced thrombocytopenia, severe hypoxemia, hyperlactemia, severe hypocalcemia, metabolic alkalosis, and intractable hypernatremia; 3) Life expectancy of less than 3 months; 4) Severe cardiac, hepatic, or respiratory dysfunction, patients with malignant tumors; 5) Unable or unwilling to sign an informed consent form; 6) Participation in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of major bleeding events; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence rate of non-major bleeding events;Anticoagulation effects;Dialysis Adequacy;side effects; | — |
Countries
China
Contacts
Public ContactWang Xiaohua
The Seventh Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed